Home > Insider Trading > Filing (0001103021-20-000010)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1720772	Theresa Mary Coelho	C/O Biodelivery Sciences Intl, Inc. 4131 Parklake Ave. Suite 225 Raleigh NC 27612	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-15	18,333	$0.00	18,333	No	4	M	Direct
Common Stock	Acquisiton	2020-01-15	35,703	$3.73	54,036	No	4	M	Direct
Common Stock	Disposition	2020-01-16	42,018	$5.98	12,018	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-01-15	18,333	$0.00	18,333	$0.00
Common Stock	Stock Options (right to buy)	Disposition	2020-01-15	35,703	$3.73	35,703	$3.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
36,667	2020-01-15	2022-01-17	No	4	M	Direct
71,406	2020-01-15	2029-01-17	No	4	M	Direct

Footnotes

The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan.
On January 16, 2020, the Reporting Person sold an aggregate of 42,018 shares of the Issuer's Common Stock at a weighted average price of $5.98 per share. The highest sale price for the Common Stock was $6.00 per share and the lowest sale price was $5.89 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 18,333 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022.
The shares of common stock were acquired by the Reporting Person as a result of the exercise of stock options granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the stock options under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022.